
    
      The trial has two parts: firstly, to explore the maximum tolerated dosage(MTD) of
      bendamustine in the combination of pomalidomide and dexamethasone in relapsed or refractory
      multiple myeloma; secondly, to find out efficacy and safety of pomalidomide and bendamustine
      with dexamethasone in relapsed or refractory multiple myeloma in an expanded cohort.
    
  